These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26329535)

  • 21. Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group.
    Young LD; Kreiner PW; Panas L
    Pain Med; 2018 Jul; 19(7):1396-1407. PubMed ID: 28383713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review.
    Johnston K; Alley L; Novak K; Haverly S; Irwin A; Hartung D
    J Am Pharm Assoc (2003); 2018; 58(5):568-576. PubMed ID: 30030040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances.
    Fass JA; Hardigan PC
    J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How does use of a prescription monitoring program change pharmacy practice?
    Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
    J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An opioid dispensing and misuse prevention algorithm for community pharmacy practice.
    Rickles NM; Huang AL; Gunther MB; Chan WJ
    Res Social Adm Pharm; 2019 Aug; 15(8):959-965. PubMed ID: 29525483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacists' attitudes toward and practices with adolescents.
    Conard LA; Fortenberry JD; Blythe MJ; Orr DP
    Arch Pediatr Adolesc Med; 2003 Apr; 157(4):361-5. PubMed ID: 12695232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
    Riley TB; Alemagno S
    Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of an automated dispensing system in outpatient pharmacies.
    Humphries TL; Delate T; Helling DK; Richardson B
    J Am Pharm Assoc (2003); 2008; 48(6):774-9. PubMed ID: 19019807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combating the prescription painkiller epidemic: a national prescription drug reporting program.
    Shepherd J
    Am J Law Med; 2014; 40(1):85-112. PubMed ID: 24844043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter?
    Fleming ML; Chandwani H; Barner JC; Weber SN; Okoro TT
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):136-42. PubMed ID: 23688495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of state prescription drug monitoring programs: a state-by-state survey.
    Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abuse and Misuse of Prescription and Nonprescription Drugs from Community Pharmacies in Aden City-Yemen.
    Abood EA; Wazaify M
    Subst Use Misuse; 2016 Jun; 51(7):942-7. PubMed ID: 27100671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Styles and Practice Policies: Influence on Communication with Patients Regarding Worrisome Prescription Drug Monitoring Program Data.
    Hildebran C; Leichtling G; Irvine JM; Cohen DJ; Hallvik SE; Deyo RA
    Pain Med; 2016 Nov; 17(11):2061-2066. PubMed ID: 27009292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors.
    Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Hagaman A; Pack RP
    Res Social Adm Pharm; 2016; 12(6):937-948. PubMed ID: 26806859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
    Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
    J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical care in a community-based practice setting in Jordan: where are we now with our attitudes and perceived barriers?
    Aburuz S; Al-Ghazawi M; Snyder A
    Int J Pharm Pract; 2012 Apr; 20(2):71-9. PubMed ID: 22416931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse.
    Grecu AM; Dave DM; Saffer H
    J Policy Anal Manage; 2019; 38(1):181-209. PubMed ID: 30572414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
    Picco L; Lam T; Xia T; Nielsen S
    Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.